Organovo Holdings
Developer of 3D human tissue models and bioprinting technologies for drug discovery, preclinical safety testing, and therapeutic development. Activities include automated fabrication of multicellular human tissues, in vitro disease modeling (liver, kidney, intestinal, bone, oncology), development of small-molecule therapeutics informed by 3D tissue data, and collaborative partnerships with pharmaceutical and cosmetics companies. The company reports an FDA clinical trial authorization for an oral FXR agonist candidate for Phase 2 ulcerative colitis studies.
Industries
Nr. of Employees
medium (51-250)
Organovo Holdings
San Diego, California, United States, North America
Products
3D human liver tissue for toxicology and preclinical testing
Organotypic human liver tissue constructs intended for in vitro toxicology, fibrosis modeling, and assessment of drug-induced liver injury.
3D human kidney tissue and organoids for nephrotoxicity testing
Bioprinted kidney proximal tubule tissues and pluripotent stem cell–derived kidney organoids for evaluation of drug-induced nephrotoxicity and high-content screening.
Oral FXR agonist therapeutic candidate (lead clinical program)
An orally delivered FXR agonist advanced into clinical development with FDA authorization for a Phase 2 trial in ulcerative colitis; also being advanced for other inflammatory bowel and liver diseases.
3D human liver tissue for toxicology and preclinical testing
Organotypic human liver tissue constructs intended for in vitro toxicology, fibrosis modeling, and assessment of drug-induced liver injury.
3D human kidney tissue and organoids for nephrotoxicity testing
Bioprinted kidney proximal tubule tissues and pluripotent stem cell–derived kidney organoids for evaluation of drug-induced nephrotoxicity and high-content screening.
Oral FXR agonist therapeutic candidate (lead clinical program)
An orally delivered FXR agonist advanced into clinical development with FDA authorization for a Phase 2 trial in ulcerative colitis; also being advanced for other inflammatory bowel and liver diseases.
Services
Design and supply of human-relevant 3D tissue models and collaborative research to support drug discovery, toxicology testing, and product evaluation.
Design and supply of human-relevant 3D tissue models and collaborative research to support drug discovery, toxicology testing, and product evaluation.
Expertise Areas
- 3D bioprinting and tissue fabrication
- In vitro disease modeling
- Preclinical toxicology testing
- Medicinal chemistry guided by human tissue models
Key Technologies
- 3D bioprinting / additive tissue fabrication
- Organotypic human tissue models
- Primary human cell culture
- Organoid generation (kidney, liver, intestinal models)
News & Updates
Press release about transition of 3D bioprinting activities to VivoSim.
Corporate update on cash position and listing status.
Corporate business update.
Peer-reviewed publication describing use of 3D bioprinting to model tumor phenotypes (Cell Reports, 2019).
Peer-reviewed publication describing intestinal 3D tissue models and ADME/Tox applications (iScience, 2018).
Press release about transition of 3D bioprinting activities to VivoSim.
Corporate update on cash position and listing status.
Corporate business update.
Peer-reviewed publication describing use of 3D bioprinting to model tumor phenotypes (Cell Reports, 2019).
Peer-reviewed publication describing intestinal 3D tissue models and ADME/Tox applications (iScience, 2018).